Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb
The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.
The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.